LCC Therapeutics

LCC Therapeutics, founded in 2014 at the University of Liverpool in the UK, has long been committed to the research and development of novel molecular design and synthesis technologies, particularly for new chiral molecules. The company’s PACE (Parallel Automated Chiral Engine) technology platform integrates AI software with automation technology, enabling virtual screening of target molecules within a chiral chemical library of hundreds of millions of molecules. With the help of automated equipment, it efficiently completes synthesis and proceeds to physical testing. This platform has already served several well-known multinational pharmaceutical companies.